| Wissenschaftl. Titel | A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment |
| Erkrankung |
Niere/Harnwege:
Nierenzellkrebs:
Zweitlinie oder höher
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
erstellt 30.12.2020 Student Studienregister
geändert 22.08.2022 Student Studienregister